Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients

Acta Haematologica

Volumn 122, Issue 4, 2009, Pages 226-229

  Costa, Elísio ^a,b   Swinkels, Dorine W ^i,j   Laarakkers, Coby M ⁱ   Rocha Pereira, Petronila ^e   Rocha, Susana ^b,c   Reis, Flávio ^f   Teixeira, Frederico ^f   Miranda, Vasco ^g   Do Sameiro Faria, Maria ^g   Loureiro, Alfredo ^h   Quintanilha, Alexandre ^b,d   Belo, Luís ^b,c   Santos Silva, Alice ^b,c  

^a CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Faculdade de Farmácia

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^f UNIVERSITY OF COIMBRA   (Portugal)

^g FRESENIUS MEDICAL CARE PORTUGAL   (Portugal)

^h Uninefro Santo Tirso Sociedade Prestadora de Cuidados Medicos e Dialise SA   (Portugal)

ⁱ Hepcidinanalysiscom ^*

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEPCIDIN; INTERLEUKIN 6; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IRON BLOOD LEVEL; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DRUG RESISTANCE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TRANSFERRIN;

EID: 70350521582     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253590     Document Type: Article

References (9)

1. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S: Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002; 29: 327-353.
2. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W: Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anemia. Gut 2004; 53: 735-743.
3. Dallalio G, Fleury T, Means RT: serum hepcidin in clinical specimens. Br J Haematol 2003; 122: 996-1000.
4. Hsu SP, Ching CK, Chien CT, Hung KY: Plasma prohepcidin positively correlates with haematocrit in chronic hemodialysis patients. Blood Purif 2006; 24: 311-316.
5. Costa E, Pereira BJG, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A: Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol 2008; 28: 677-683.
6. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I: The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dialysis 2009; 22: 70-77.
7. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 2008; 3:e2706.
8. Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, Swinkels DW: (Pre)analytical imprecision, betweensubject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem 2009; 389: 124-129.
9. Furaso M, Munaretto G, Spinello M, Rebeschini M, Amici G, Gallieni M, Picoli A: Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. J Nephrol 2005; 18: 72-79.